Drug Trial Radar · NCT02597933
A Trial to Compare Nintedanib With Placebo for Patients With Scleroderma Related Lung Fibrosis
Last checked: Nov 20, 2026Latest source record: Dec 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
580
Actual
Start
Nov 12, 2015
Primary completion
Oct 31, 2018
Study completion Nov 28, 2018
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Nov 5, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Systemic Sclerosis (SSc) is a devastating disease of unknown etiology. Patients suffer from multiple organ fibrosis whereas lung fibrosis (interstitial lung disease, ILD) is one of the main driver for mortality. There is preclinical evidence for efficacy of nintedanib in SSc and associated ILD (SSc-ILD) and the anti-fibrotic efficacy of nintedanib was proven in idiopathic pulmonary fibrosis patients, who are presenting a similar pattern regarding lung fibrosis. Hence it is the purpose of the trial to confirm the efficacy and safety of nintedanib 150 mg bid in treating patients with SSc-ILD, compared with placebo. The trial will be conducted as a double blind, randomised, placebo-controlled trial with primary efficacy evaluation at week 52 and placebo-controlled treatment until last patient out (up to a maximum of 100 weeks). Respiratory function is globally accepted for assessment of treatment effects in patients with lung fibrosis. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in patients with SSc-ILD.
Conditions
- Scleroderma, Systemic
Interventions
NintedanibDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 WeeksTime frame: up to week (wk) 52 after the start of administration
Locations
195 sites in 32 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of California Los Angeles
Los Angeles, California
University of California Davis
Sacramento, California
University of California San Francisco
San Francisco, California
Stanford University Medical Center
Stanford, California
University of Colorado Denver
Aurora, Colorado
Yale University School of Medicine
New Haven, Connecticut
Georgetown University
Washington D.C., District of Columbia
University of Florida College of Medicine
Jacksonville, Florida
University of Miami
Miami, Florida
The Emory Clinic
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
University of Louisville
Louisville, Kentucky
Tulane University Hospital and Clinic
New Orleans, Louisiana
Johns Hopkins Hospital
Baltimore, Maryland
Boston Medical Center
Boston, Massachusetts
University of Michigan Health System
Ann Arbor, Michigan
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota
Mayo Clinic-Rochester
Rochester, Minnesota
The Lung Research Center, LLC
Chesterfield, Missouri
Washington University School of Medicine
St Louis, Missouri
Hospital for Special Surgery
New York, New York
Icahn School of Medicine at Mount Sinai
New York, New York
Columbia University Medical Center-New York Presbyterian Hospital
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati Health
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
University of Toledo
Toledo, Ohio
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
Temple University Hospital
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
University of South Carolina
Columbia, South Carolina
Vanderbilt Pulmonary Clinic
Nashville, Tennessee
University of Texas Southwestern Medical Center
Dallas, Texas
The University Of Texas at Houston
Houston, Texas
University of Utah Health Sciences Center
Salt Lake City, Utah
Showing 40 of 195 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.